Advertisement

Archives of Pharmacal Research

, 31:1457 | Cite as

Neuroprotective effects of chronic hesperetin administration in mice

  • Eun Jeong Choi
  • Woong Shick Ahn
Research Article Drug Efficacy and Safety

Abstract

Flavonoids are considered therapeutic agents in neurodegenerative disease because of their neuroprotective activity. This study investigated the neuroprotective effects of hesperetin in the brains of mice administered hesperetin at 10 or 50 mg/kg body weight (BW) for five weeks. Hesperetin inhibited biomarkers of oxidative stress, such as the level of thiobarbituric acid-reactive substance (TBARS) and carbonyl content, although there was a significant reduction at the higher dose of hesperetin. Moreover, at the higher dose, hesperetin significantly activated the catalase and total superoxide dismutase (SOD) activities. The same patterns were observed in the protein expression, and the expression of CuZn-SOD was more pronounced than that of Mn-SOD. The reduced glutathione (GSH)/oxidized glutathione (GSSG) ratio was increased significantly in a dose-dependent manner, as well as the glutathione peroxidase (GSH-px) and glutathione reductase (GR) activities. Moreover, hesperetin did not induce apoptosis, even at the higher dose, as evidenced by caspase-3 expression and its activity. Based on these results, hesperetin may have a neuroprotective effect via the inhibition of oxidative damage, together with activation of the antioxidant enzyme system.

Key words

Antioxidant Apoptosis Hesperetin In vivo Neuroprotective 

References

  1. Adams, J. D. Jr., Klaidman, L. K., Odunze, I. N., Shen, H. C., and Miller, C. A., Alzheimer’s and Parkinson’s disease. Brain levels of glutathione, glutathione disulfide, and vitamin E. Mol. Chem. Neuropathol., 14, 213–226 (1991).PubMedCrossRefGoogle Scholar
  2. Aebi, H., Catalase in vitro. Methods Enzymol., 105, 121–126 (1984).PubMedCrossRefGoogle Scholar
  3. Aldini, G., Dalle-Donne, I., Facino, R. M., Milzani, A., and Carini, M., Intervention strategies to inhibit protein carbonylation by lipoxidation-derived reactive carbonyls. Med. Res. Rev., 27, 817–868 (2007).PubMedCrossRefGoogle Scholar
  4. Ansari, M. A., Joshi, G., Huang, Q., Opii, W. O., Abdul, H. M., Sultana, R., and Butterfield, D. A., In vivo administration of D609 leads to protection of subsequently isolated gerbil brain mitochondria subjected to in vitro oxidative stress induced by amyloid beta-peptide and other oxidative stressors: relevance to Alzheimer’s disease and other oxidative stress-related neurodegenerative disorders. Free Radic. Biol. Med., 41, 1694–1703 (2006).PubMedCrossRefGoogle Scholar
  5. Bharath, S., Hsu, M., Kaur, D., Rajagopalan, S., and Andersen, J. K., Glutathione, iron and Parkinson’s disease. Biochem. Pharmacol., 64, 1037–1048 (2002).PubMedCrossRefGoogle Scholar
  6. Bonilla, E., Huntington disease. Invest. Clin., 41, 117–141 (2000).PubMedGoogle Scholar
  7. Carlberg, I. and Mannervik, B., Glutathione reductase. Methods Enzymol., 113, 484–490 (1985).PubMedCrossRefGoogle Scholar
  8. Cho, J., Antioxidant and neuroprotective effects of hesperidin and its aglycone hesperetin. Arch. Pharm. Res., 29, 699–706 (2006).PubMedCrossRefGoogle Scholar
  9. Choi, E. J., Kim, G. D., Chee, K. M., and Kim, G. H., Effects of hesperetin on vessel structure formation in mouse embryonic stem (mES) cells. Nutrition, 22, 947–951 (2006).PubMedCrossRefGoogle Scholar
  10. Choi, E. J., Antioxidative effects of hesperetin against 7,12-dimethylbenz(a)anthracene-induced oxidative stress in mice. Life Sci., 82, 1059–1064 (2008).PubMedCrossRefGoogle Scholar
  11. Cooper, A. J. L., Glutathione in the brain: disorders of glutathione metabolism: The Molecular and Genetic Basis of Neurological Disease. Butterworth-Heinemann, Boston, 1997, pp. 1195–1230, (1997).Google Scholar
  12. Cruz-Aguado, R., Turner, L. F., Diaz, C. M., and Pinero, J., Nerve growth factor and striatal glutathione metabolism in a rat model of Huntington’s disease. Restor. Neurol. Neurosci., 17, 217–221 (2000).PubMedGoogle Scholar
  13. Erdem, E., Carlier, R., Idir, A. B., Masnou, P. O., Moulonguet, A., Adams, D., and Doyon, D., Gadolinium-enhanced MRI in central nervous system Behçet’s disease. Neuroradiology, 35, 142–144 (1993).PubMedCrossRefGoogle Scholar
  14. Flohé, L. and Günzler, W. A., Assays of glutathione peroxidase. Methods Enzymol., 105, 114–121 (1984).PubMedCrossRefGoogle Scholar
  15. Fridovich, I., Superoxide anion radical (O2−.), superoxide dismutases, and related matters. J. Biol. Chem., 272, 18515–18517 (1997).PubMedCrossRefGoogle Scholar
  16. Fridovich, I., Superoxide radical and superoxide dismutases. Annu. Rev. Biochem., 64, 97–112 (1995).PubMedCrossRefGoogle Scholar
  17. Garg, A., Garg, S., Zaneveld, L. J., and Singla, A. K., Chemistry and pharmacology of the Citrus bioflavonoid hesperidin. Phytother. Res., 15, 655–669 (2001).PubMedCrossRefGoogle Scholar
  18. Hirrlinger, J., Schulz, J. B., and Dringen, R., Effects of dopamine on the glutathione metabolism of cultured astroglial cells: implications for Parkinson’s disease. J. Neurochem., 82, 458–467 (2002).PubMedCrossRefGoogle Scholar
  19. Hissin, P. J. and Hilf, R., A fluorometric method for determination of oxidized and reduced glutathione in tissues. Anal. Biochem., 74, 214–226 (1976).PubMedCrossRefGoogle Scholar
  20. Ho, Y. S., Magnenat, J. L., Bronson, R. T., Cao, J., Gargano, M., Sugawara, M., and Funk, C. D., Mice deficient in cellular glutathione peroxidase develop normally and show no increased sensitivity to hyperoxia. J. Biol. Chem., 272, 16644–16651 (1997a).PubMedCrossRefGoogle Scholar
  21. Ho, Y. S., Swenson, L., Derewenda, U., Serre, L., Wei, Y., Dauter, Z., Hattori, M., Adachi, T., Aoki, J., Arai, H., Inoue, K., and Derewenda, Z. S., Brain acetylhydrolase that inactivates platelet-activating factor is a G-protein-like trimer. Nature, 385, 89–93 (1997b).PubMedCrossRefGoogle Scholar
  22. Hwang, S. L. and Yen, G. C., Neuroprotective effects of the citrus flavanones against H2O2-induced cytotoxicity in PC12 cells. J. Agric. Food Chem., 859–864 (2008).Google Scholar
  23. Jaeger, A., Wälti, M., and Neftel, K., Side effects of flavonoids in medical practice. Prog. Clin. Biol. Res., 280, 379–394 (1988).PubMedGoogle Scholar
  24. Kim, J. Y., Jung, K. J., Choi, J. S., and Chung, H. Y., Hesperetin: a potent antioxidant against peroxynitrite. Free Radic. Res., 38, 761–769 (2004).PubMedCrossRefGoogle Scholar
  25. Marklund, S. and Marklund, G., Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur. J. Biochem., 47, 469–474 (1974).PubMedCrossRefGoogle Scholar
  26. Moreira, P. I., Siedlak, S. L., Aliev, G., Zhu, X., Cash, A. D., Smith, M. A., and Perry, G., Oxidative stress mechanisms and potential therapeutics in Alzheimer disease. J. Neural Transm., 112, 921–932 (2005).PubMedCrossRefGoogle Scholar
  27. Nunomura, A., Moreira, P. I., Lee, H. G., Zhu, X., Castellani, R. J., Smith, M. A., and Perry, G., Neuronal death and survival under oxidative stress in Alzheimer and Parkinson diseases. CNS Neurol. Disord. Drug Targets, 6, 411–423 (2007).PubMedCrossRefGoogle Scholar
  28. Ohkawa, H., Ohishi, N., and Yagi, K., Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem., 95, 351–358 (1979).PubMedCrossRefGoogle Scholar
  29. Pollard, S. E., Whiteman, M., and Spencer, J. P., Modulation of peroxynitrite-induced fibroblast injury by hesperetin: a role for intracellular scavenging and modulation of ERK signaling. Biochem. Biophys. Res. Commun., 347, 916–923 (2006).PubMedCrossRefGoogle Scholar
  30. Rao, A. V. and Balachandran, B., Role of oxidative stress and antioxidants in neurodegenerative diseases. Nutr. Neurosci., 5, 291–309 (2002).PubMedCrossRefGoogle Scholar
  31. Reznick, A. Z. and Packer, L., Oxidative damage to proteins: spectrophotometric method for carbonyl assay. Methods Enzymol., 233, 357–363 (1994).PubMedCrossRefGoogle Scholar
  32. Ross, J. A. and Kasum, C. M., Dietary flavonoids: bioavailability, metabolic effects, and safety. Annu. Rev. Nutr., 22, 19–34 (2002).PubMedCrossRefGoogle Scholar
  33. Sian, J., Dexter, D. T., Lees, A. J., Daniel, S., Agid, Y., Javoy-Agid, F., Jenner, P., and Marsden, C. D., Alterations in glutathione levels in Parkinson’s disease and other neurodegenerative disorders affecting basal ganglia. Ann. Neurol., 36, 348–355 (1994).PubMedCrossRefGoogle Scholar
  34. Suk, K., Regulation of neuroinflammation by herbal medicine and its implications for neurodegenerative diseases. A focus on traditional medicines and flavonoids. Neurosignals., 14, 23–33 (2005).PubMedCrossRefGoogle Scholar
  35. Zhu, Y., Carvey, P. M., and Ling, Z., Age-related changes in glutathione and glutathione-related enzymes in rat brain. Brain Res., 1090, 35–44 (2006).PubMedCrossRefGoogle Scholar

Copyright information

© The Pharmaceutical Society of Korea 2008

Authors and Affiliations

  1. 1.Cancer Research InstituteThe Catholic University of KoreaSeoulKorea
  2. 2.Department of Obstetrics and Gynecology, College of MedicineThe Catholic University of KoreaSeoulKorea

Personalised recommendations